Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) Return on Capital Employed (2017 - 2025)

Historic Return on Capital Employed for UroGen Pharma (URGN) over the last 9 years, with Q3 2025 value amounting to 0.86%.

  • UroGen Pharma's Return on Capital Employed fell 5400.0% to 0.86% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.86%, marking a year-over-year decrease of 5400.0%. This contributed to the annual value of 0.52% for FY2024, which is 0.0% changed from last year.
  • According to the latest figures from Q3 2025, UroGen Pharma's Return on Capital Employed is 0.86%, which was down 5400.0% from 0.68% recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's Return on Capital Employed ranged from a high of 0.32% in Q3 2024 and a low of 1.23% during Q1 2021
  • Moreover, its 5-year median value for Return on Capital Employed was 0.68% (2025), whereas its average is 0.68%.
  • In the last 5 years, UroGen Pharma's Return on Capital Employed skyrocketed by 5900bps in 2024 and then tumbled by -5400bps in 2025.
  • Over the past 5 years, UroGen Pharma's Return on Capital Employed (Quarter) stood at 0.88% in 2021, then rose by 17bps to 0.73% in 2022, then skyrocketed by 42bps to 0.42% in 2023, then grew by 8bps to 0.39% in 2024, then tumbled by -121bps to 0.86% in 2025.
  • Its Return on Capital Employed stands at 0.86% for Q3 2025, versus 0.68% for Q2 2025 and 0.48% for Q1 2025.